Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA

American Journal of Cardiology

Volumn 92, Issue 12, 2003, Pages 1492-1494

  Wang, John C ^a   Aucoin Barry, Denise ^b   Manuelian, Deborah ^b   Monbouquette, Rachele ^b   Reisman, Mark ^b   Gray, William ^b   Block, Peter C ^b   Block, Elizabeth H ^b   Ladenheim, Marc ^b   Simon, Daniel I ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BIOASSAY; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE ANOMALY; ULTEGRA RAPID PLATELET FUNCTION ASSAY ASA;

EID: 10744230699     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.08.072     Document Type: Article

References (12)

1. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 105:2002;1650-1655.
2. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 88:2001;230-235.
3. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 41:2003;961-965.
4. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res. 63:1991;587-593.
5. Tohgi H., Konno S., Tamura K., Kimura B., Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 23:1992;1400-1403.
6. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., Brace L.D. Aspirin response and failure in cerebral infarction. Stroke. 24:1993;345-350.
7. Pappas J.M., Westengard J.C., Bull B.S. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med. 118:1994;801-804.
8. Mueller M.R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., Koppensteiner R., Ergun E., Mittlboeck M., Schreiner W., Losert U., Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 78:1997;1003-1007.
9. Hurlen M., Seljeflot I., Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J. 32:1998;233-237.
10. Grotemeyer K.H. The platelet-reactivity-test-a useful "by-product" of the blood-sampling procedure? Thromb Res. 61:1991;423-431.
11. Grotemeyer K.H., Scharafinski H.W., Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 71:1993;397-403.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.